BARDA backs GSK antibiotic with $94M in R&D support

The U.S. government's bioterror drug development arm, BARDA, has stepped up with a $94 million contract to support the development of a new gram-negative antibiotic in GlaxoSmithKline's ($GSK) pipeline. In-licensed from Anacor, GSK '052 now has ample R&D support over the next four years to back Phase II clinical trials for ventilator-associated pneumonia and Phase III trials for complicated intra-abdominal infections. "BARDA's financial support for the development of GSK '052 will help ensure the rapid development of this compound toward its approval in all relevant indications," said Anacor CEO David Perry. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.